Selected Cytokines, Characteristics, and Current and Potential Therapeutic Applications Flashcards
Primary cell source of EPO
Kidney (peritubular interstitial cell)
Primary target cell of EPO
Bone marrow erythroid progenitors (BFU-E and CFU-E)
Biologic activity of EPO
Simulates proliferation of erythroid progenitors and prevents apoptosis of CFU-E
Current/Potential therapy application of EPO
Anemia of chronic renal disease (in predialysis, dialysis dependent, and chronic anemia patients)
Treatment of anemia in cancer patients on chemotherapy
Autologous predonation blood collection
Anemia in HIV infection to permit use of zidovudine (AZT)
Post autologous hematopoietic stem cell transplant
Primary cell source of G-CSF
Endothelial cells
Placenta
Monocytes
Macrophages
Primary target cell of G-CSF
Neutrophil precursors
Fibroblasts
Leukemic myeloblasts
Biologic activity of G-CSF
Stimulates granulocyte colonies
Differentiation of progenitors toward neutrophil lineage
Stimulation of neutrophil maturation
Current/Potential therapy application of G-CSF
Chemotherapy-induced neutropenia
Stem cell mobilization
Peripheral blood/bone marrow transplantation
Congenital neutropenia
Idiopathic neutropenia
Cyclic neutropenia
Primary cell source of GM-CSF
T cells
Macrophages
Endothelial cells
Fibroblasts
Mast cells
Primary target cell of GM-CSF
Bone marrow progenitor cells
Dendritic cells
Macrophages
NKT cells
Biologic activity of GM-CSF
Promotes antigen presentation
T cell homeostasis
Hematopoietic cell growth factor
Current/Potential therapy application of GM-CSF
Chemotherapy-induced neutropenia
Stem cell mobilization
Peripheral blood/bone marrow transplantation
Leukemia treatment
Primary cell source of IL-2
CD4+ T cells
NK cells
B cells
Primary target cell of IL-2
T cells
NK cells
B cells
Monocytes
Biologic activity of IL-2
Cell growth/activation of CD4+ and CD8+ T cells
Suppress T-reg responses
Mediator of immune tolerance
Current/Potential therapy application of IL-2
Metastatic melanoma
Renal cell carcinoma
Non-Hodgkin lymphoma
Asthma
Primary cell source of IL-3
Activated T cells
NK cells
Primary target cell of IL-3
Hematopoietic stem cells and progenitors
Biologic activity of IL-3
Proliferation of hematopoietic progenitors
Current/Potential therapy application of IL-3
Stem cell mobilization
Postchemotherapy/transplantation
Bone marrow failure states
Primary cell source of IL-6
T cells
Macrophages
Fibroblasts
Primary target cell of IL-6
T cells
B cells
Liver
Biologic activity of IL-6
Costimulation with other cytokines
Cell growth/activation of T cells and B cells
Megakaryocyte maturation
Neural differentiation
Acute phase reactant
Current/Potential therapy application of IL-6
Stimulation of platelet production, but not at tolerable doses
Melanoma
Renal cell carcinoma
IL-6 inhibitors may be promising
Primary cell source of IL-10
CD4+, Th2 T cells
CD8+ T cells
Monocytes
Macrophages
Primary target cell of IL-10
T cells
Macrophages
Biologic activity of IL-10
Inhibits cytokine production
Inhibits macrophages
Current/Potential therapy application of IL-10
Target lymphokines in prevention of B cell lymphoma and Epstein-Barr virus lymphomagenesis
HIV infection
Primary cell source of IL-12
Macrophages
Primary target cell of IL-12
T cells
Biologic activity of IL-12
T cell, Th1 differentiation
Current/Potential therapy application of IL-12
Allergy treatment
Adjuvant for infectious disease therapy
Asthma
Possible role for use in vaccines
Primary cell source of IL-15
Activated CD4+
T cells
Primary target cell of IL-15
CD4+ T cells
CD8+ T cells
NK cells
Biologic activity of IL-15
CD4+/CD8+ T cell proliferation
CD8+/NK cell cytotoxicity
Current/Potential therapy application of IL-15
Melanoma
Rheumatoid arthritis
Adoptive cell therapy
Generation of antigen-specific T cells
Primary cell source of IFN-a
Dendritic cells
NK cells
T cells
B cells
Macrophages
Fibroblasts
Endothelial cells
Osteoblasts
Primary target cell of IFN-a
Macrophages
NK cells
Biologic activity of IFN-a
Antiviral
Enhances MHC expression
Current/Potential therapy application of IFN-a
Adjuvant treatment for stage II/III melanoma
Hematologic malignancies: Kaposi sarcoma, hairy cell leukemia, and chronic myelogenous leukemia